Adoptive  ||| S:0 E:9 ||| JJ
T-cell  ||| S:9 E:16 ||| JJ
therapy  ||| S:16 E:24 ||| NN
of  ||| S:24 E:27 ||| IN
cancer  ||| S:27 E:34 ||| NN
Adoptive  ||| S:34 E:43 ||| NNP
immunotherapy  ||| S:43 E:57 ||| NN
is  ||| S:57 E:60 ||| VBZ
determined  ||| S:60 E:71 ||| VBN
as  ||| S:71 E:74 ||| IN
the  ||| S:74 E:78 ||| DT
isolation  ||| S:78 E:88 ||| NN
of  ||| S:88 E:91 ||| IN
antigen-specific  ||| S:91 E:108 ||| JJ
cells ||| S:108 E:113 ||| NNS
,  ||| S:113 E:115 ||| ,
their  ||| S:115 E:121 ||| PRP$
ex  ||| S:121 E:124 ||| JJ
vivo  ||| S:124 E:129 ||| JJ
expansion  ||| S:129 E:139 ||| NN
and  ||| S:139 E:143 ||| CC
activation ||| S:143 E:153 ||| NN
,  ||| S:153 E:155 ||| ,
and  ||| S:155 E:159 ||| CC
subsequent  ||| S:159 E:170 ||| JJ
autologous  ||| S:170 E:181 ||| JJ
administration  ||| S:181 E:196 ||| NN
and  ||| S:196 E:200 ||| CC
is  ||| S:200 E:203 ||| VBZ
a  ||| S:203 E:205 ||| DT
promising  ||| S:205 E:215 ||| JJ
approach  ||| S:215 E:224 ||| NN
to  ||| S:224 E:227 ||| TO
inducing  ||| S:227 E:236 ||| VB
antitumour  ||| S:236 E:247 ||| JJ
immune  ||| S:247 E:254 ||| JJ
responses ||| S:254 E:263 ||| NNS
.  ||| S:263 E:265 ||| .
Identification  ||| S:265 E:280 ||| NN
of  ||| S:280 E:283 ||| IN
tumour  ||| S:283 E:290 ||| JJ
antigens  ||| S:290 E:299 ||| NN
and  ||| S:299 E:303 ||| CC
monitoring  ||| S:303 E:314 ||| VBG
the  ||| S:314 E:318 ||| DT
persistence  ||| S:318 E:330 ||| NN
and  ||| S:330 E:334 ||| CC
transport  ||| S:334 E:344 ||| NN
of  ||| S:344 E:347 ||| IN
transferred  ||| S:347 E:359 ||| JJ
cells  ||| S:359 E:365 ||| NNS
has  ||| S:365 E:369 ||| VBZ
provided  ||| S:369 E:378 ||| VBN
our  ||| S:378 E:382 ||| PRP$
understanding  ||| S:382 E:396 ||| NN
over  ||| S:396 E:401 ||| IN
the  ||| S:401 E:405 ||| DT
mechanisms  ||| S:405 E:416 ||| NNS
of  ||| S:416 E:419 ||| IN
tumour  ||| S:419 E:426 ||| JJ
immunotherapy ||| S:426 E:439 ||| NN
.  ||| S:439 E:441 ||| .
Cell-transfer  ||| S:441 E:455 ||| JJ
therapies  ||| S:455 E:465 ||| NNS
have  ||| S:465 E:470 ||| VBP
seemed  ||| S:470 E:477 ||| VBN
beneficial  ||| S:477 E:488 ||| JJ
for  ||| S:488 E:492 ||| IN
the  ||| S:492 E:496 ||| DT
treatment  ||| S:496 E:506 ||| NN
of  ||| S:506 E:509 ||| IN
patients  ||| S:509 E:518 ||| NNS
with  ||| S:518 E:523 ||| IN
selected  ||| S:523 E:532 ||| JJ
metastatic  ||| S:532 E:543 ||| JJ
cancers  ||| S:543 E:551 ||| NNS
by  ||| S:551 E:554 ||| IN
providing  ||| S:554 E:564 ||| VBG
a  ||| S:564 E:566 ||| DT
blueprint  ||| S:566 E:576 ||| NN
for  ||| S:576 E:580 ||| IN
the  ||| S:580 E:584 ||| DT
wider  ||| S:584 E:590 ||| JJR
application  ||| S:590 E:602 ||| NN
of  ||| S:602 E:605 ||| IN
adoptive  ||| S:605 E:614 ||| JJ
cell  ||| S:614 E:619 ||| NN
transfer  ||| S:619 E:628 ||| NN
( ||| S:628 E:629 ||| -LRB-
ACT ||| S:629 E:632 ||| NNP
)  ||| S:632 E:634 ||| -RRB-
therapy ||| S:634 E:641 ||| NN
,  ||| S:641 E:643 ||| ,
and  ||| S:643 E:647 ||| CC
emphasize  ||| S:647 E:657 ||| VB
the  ||| S:657 E:661 ||| DT
requirement  ||| S:661 E:673 ||| NN
for  ||| S:673 E:677 ||| IN
in  ||| S:677 E:680 ||| IN
vivo  ||| S:680 E:685 ||| JJ
persistence  ||| S:685 E:697 ||| NN
of  ||| S:697 E:700 ||| IN
the  ||| S:700 E:704 ||| DT
cells  ||| S:704 E:710 ||| NNS
for  ||| S:710 E:714 ||| IN
therapeutic  ||| S:714 E:726 ||| JJ
efficacy ||| S:726 E:734 ||| NN
.  ||| S:734 E:736 ||| .
The  ||| S:736 E:740 ||| DT
magnitude  ||| S:740 E:750 ||| NN
and  ||| S:750 E:754 ||| CC
specificity  ||| S:754 E:766 ||| NN
of  ||| S:766 E:769 ||| IN
immune  ||| S:769 E:776 ||| JJ
responses  ||| S:776 E:786 ||| NNS
to  ||| S:786 E:789 ||| TO
pathogenic  ||| S:789 E:800 ||| VB
organisms  ||| S:800 E:810 ||| NNS
have  ||| S:810 E:815 ||| VBP
let  ||| S:815 E:819 ||| VB
a  ||| S:819 E:821 ||| DT
search  ||| S:821 E:828 ||| NN
for  ||| S:828 E:832 ||| IN
ways  ||| S:832 E:837 ||| NNS
to  ||| S:837 E:840 ||| TO
arm  ||| S:840 E:844 ||| VB
the  ||| S:844 E:848 ||| DT
immune  ||| S:848 E:855 ||| JJ
system  ||| S:855 E:862 ||| NN
and  ||| S:862 E:866 ||| CC
aim  ||| S:866 E:870 ||| VB
it  ||| S:870 E:873 ||| PRP
at  ||| S:873 E:876 ||| IN
a  ||| S:876 E:878 ||| DT
specific  ||| S:878 E:887 ||| JJ
type  ||| S:887 E:892 ||| NN
of  ||| S:892 E:895 ||| IN
metastatic  ||| S:895 E:906 ||| JJ
cancer ||| S:906 E:912 ||| NN
.  ||| S:912 E:914 ||| .
Knowledge  ||| S:914 E:924 ||| NN
of  ||| S:924 E:927 ||| IN
immune  ||| S:927 E:934 ||| JJ
regulation  ||| S:934 E:945 ||| NN
and  ||| S:945 E:949 ||| CC
effector  ||| S:949 E:958 ||| JJ
cell  ||| S:958 E:963 ||| NN
function  ||| S:963 E:972 ||| NNS
have  ||| S:972 E:977 ||| VBP
accumulated  ||| S:977 E:989 ||| VBN
rapidly  ||| S:989 E:997 ||| RB
in  ||| S:997 E:1000 ||| IN
the  ||| S:1000 E:1004 ||| DT
past  ||| S:1004 E:1009 ||| JJ
decade  ||| S:1009 E:1016 ||| NN
resulting  ||| S:1016 E:1026 ||| VBG
in  ||| S:1026 E:1029 ||| IN
incremental  ||| S:1029 E:1041 ||| JJ
gains  ||| S:1041 E:1047 ||| NNS
regarding  ||| S:1047 E:1057 ||| VBG
the  ||| S:1057 E:1061 ||| DT
ability  ||| S:1061 E:1069 ||| NN
to  ||| S:1069 E:1072 ||| TO
manipulate  ||| S:1072 E:1083 ||| VB
host  ||| S:1083 E:1088 ||| NN
immunity  ||| S:1088 E:1097 ||| NN
and  ||| S:1097 E:1101 ||| CC
specifically  ||| S:1101 E:1114 ||| RB
target  ||| S:1114 E:1121 ||| VB
tumour  ||| S:1121 E:1128 ||| JJ
cells  ||| S:1128 E:1134 ||| NNS
for  ||| S:1134 E:1138 ||| IN
immune  ||| S:1138 E:1145 ||| JJ
destruction ||| S:1145 E:1156 ||| NN
.  ||| S:1156 E:1158 ||| .
Besides ||| S:1158 E:1165 ||| RB
,  ||| S:1165 E:1167 ||| ,
converging  ||| S:1167 E:1178 ||| JJ
information  ||| S:1178 E:1190 ||| NN
from  ||| S:1190 E:1195 ||| IN
the  ||| S:1195 E:1199 ||| DT
fields  ||| S:1199 E:1206 ||| NNS
of  ||| S:1206 E:1209 ||| IN
molecular  ||| S:1209 E:1219 ||| JJ
biology  ||| S:1219 E:1227 ||| NN
and  ||| S:1227 E:1231 ||| CC
cellular  ||| S:1231 E:1240 ||| JJ
immunology  ||| S:1240 E:1251 ||| NN
has  ||| S:1251 E:1255 ||| VBZ
inspired  ||| S:1255 E:1264 ||| VBN
clinical  ||| S:1264 E:1273 ||| JJ
trials  ||| S:1273 E:1280 ||| NNS
using  ||| S:1280 E:1286 ||| VBG
potent  ||| S:1286 E:1293 ||| JJ
immunomodulators  ||| S:1293 E:1310 ||| NN
and  ||| S:1310 E:1314 ||| CC
molecularly  ||| S:1314 E:1326 ||| RB
defined  ||| S:1326 E:1334 ||| VBN
immunogens ||| S:1334 E:1344 ||| NN
.  ||| S:1344 E:1346 ||| .
The  ||| S:1346 E:1350 ||| DT
clinical  ||| S:1350 E:1359 ||| JJ
practice  ||| S:1359 E:1368 ||| NN
of  ||| S:1368 E:1371 ||| IN
immunotherapy  ||| S:1371 E:1385 ||| NN
for  ||| S:1385 E:1389 ||| IN
treating  ||| S:1389 E:1398 ||| VBG
cancer  ||| S:1398 E:1405 ||| NN
is  ||| S:1405 E:1408 ||| VBZ
capitalizing  ||| S:1408 E:1421 ||| VBG
on  ||| S:1421 E:1424 ||| IN
these  ||| S:1424 E:1430 ||| DT
advances ||| S:1430 E:1438 ||| NNS
,  ||| S:1438 E:1440 ||| ,
and  ||| S:1440 E:1444 ||| CC
recent  ||| S:1444 E:1451 ||| JJ
efforts  ||| S:1451 E:1459 ||| NNS
in  ||| S:1459 E:1462 ||| IN
ACT  ||| S:1462 E:1466 ||| NNP
therapy  ||| S:1466 E:1474 ||| NN
provide  ||| S:1474 E:1482 ||| VB
an  ||| S:1482 E:1485 ||| DT
excellent  ||| S:1485 E:1495 ||| JJ
example  ||| S:1495 E:1503 ||| NN
of  ||| S:1503 E:1506 ||| IN
this  ||| S:1506 E:1511 ||| DT
progress ||| S:1511 E:1519 ||| NN
.  ||| S:1519 E:1521 ||| .
